Skip to main content
. 2020 Jul 6;12(7):631. doi: 10.3390/pharmaceutics12070631

Figure 4.

Figure 4

Antibacterial activity of free RNase 3/1 and nanobioconjugates of RNase 3/1 and A against P. aeruginosa. Each sample was analyzed after 4 h of incubation in 10 mM HEPES at pH 7.4. The negative control was untreated buffer. (A) Antibacterial activity of bare MNPs for concentrations ranging from 15 to 500 µg/mL. (B) Antibacterial activity of free Ribonuclease 3/1 for concentrations ranging from 15 to 500 µg/mL. (C) Antibacterial activity MNP-RNase A and (D) MNP-RNase 3/1 nanobioconjugates for concentrations ranging from 15 to 500 µg/mL. The horizontal black dashed line represents 90% bacterial viability.